Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
Randomized, Open-label, 2-Arm, Multicenter, Phase 3 Study of Venetoclax and Azacitidine Versus Best Supportive Care as Maintenance Therapy for Patients With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy (VIALE-M)
Commercial Sponsor
AbbVie
Summary
Eligible patients will be randomised to receive up to 24-cycles of best standard care, as prescribed by their doctor, alone or in addition to up to 24-cycles of venetoclax and up to 6-cylce of azacitadine.